Thermo Fisher Scientific Inc. $TMO Position Reduced by Banque Transatlantique SA

Key Points

• Banque Transatlantique SA reduced its stake in Thermo Fisher Scientific by 3.7% in Q1, now holding 146,359 shares valued at approximately $67 million.
• Institutional investors and hedge funds own 89.23% of Thermo Fisher shares, with GAMMA Investing LLC dramatically increasing its holdings by over 60,610% during the same quarter.
• Thermo Fisher Scientific reported $5.36 EPS for the last quarter, surpassing estimates, with an upcoming quarterly dividend of $0.43 per share scheduled for October 15th.

Banque Transatlantique SA trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 146,359 shares of the medical research company's stock after selling 5,576 shares during the quarter. Thermo Fisher Scientific makes up 1.3% of Banque Transatlantique SA's portfolio, making the stock its 14th biggest position. Banque Transatlantique SA's holdings in Thermo Fisher Scientific were worth $67,303,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of TMO. GAMMA Investing LLC raised its holdings in shares of Thermo Fisher Scientific by 60,610.9% during the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares during the period. Nuveen LLC acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth $532,360,000. Farallon Capital Management LLC raised its holdings in shares of Thermo Fisher Scientific by 73.8% during the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock worth $641,577,000 after purchasing an additional 523,800 shares during the period. Sarasin & Partners LLP acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth $242,991,000. Finally, Two Sigma Advisers LP raised its holdings in shares of Thermo Fisher Scientific by 81.6% during the fourth quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company's stock worth $485,479,000 after purchasing an additional 419,200 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,666 shares of company stock worth $13,982,763. Corporate insiders own 0.33% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Barclays increased their price objective on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a report on Thursday, July 24th. HSBC reaffirmed a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a report on Friday, July 11th. William Blair assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. Finally, Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $486.82 on Wednesday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average of $456.01 and a 200-day moving average of $453.73. The firm has a market cap of $183.83 billion, a price-to-earnings ratio of 28.16, a price-to-earnings-growth ratio of 2.63 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the firm posted $5.37 EPS. The business's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.